Should a digital-health startup build vitals tech or license it?

For a digital-health startup, the pressure to balance innovation with execution is immense. Founders are constantly weighing strategic decisions that will define their trajectory, and few choices are as fundamental as whether to build core technology in-house or license it from a specialized partner. This is especially true for complex, regulated capabilities like contactless vitals monitoring. The "build vs. license" question is not merely a technical one; it is a strategic decision that impacts everything from time-to-market and capital allocation to long-term product differentiation and regulatory risk.

"Ongoing maintenance, updates, and security patches for a built-in solution can cost 15-25% of the initial development cost annually, creating a significant and recurring operational expense that licensing models typically absorb." - (Inovalon, 2024)

The core dilemma: digital health startup build vs. license vitals

The decision a digital health startup makes on build vs. license vitals technology hinges on a trade-off between control and speed. Building a proprietary vitals solution offers the promise of a perfectly tailored system and a defensible moat. However, this path is fraught with challenges that are often underestimated in the early stages of a company's life.

Building from scratch requires a significant upfront investment in not just capital, but also talent and time. Research from industry analysts consistently shows that developing even a basic, HIPAA-compliant digital health app can cost between $50,000 and $150,000 and take 4-6 months. For more complex systems involving sensor data, machine learning, and clinical-grade accuracy, such as a remote photoplethysmography (rPPG) engine for contactless vitals, these figures can easily swell to over $500,000 with development timelines stretching from 9 to 18 months. A 2024 analysis by Forbes noted that leaders often underestimate the "hidden" costs, including the specialized expertise required for signal processing, algorithm development, and navigating the extensive validation and regulatory approval processes.

Licensing a white-label or OEM solution presents a different set of trade-offs. The primary advantage is speed. A startup can integrate a pre-built, and often pre-validated, vitals monitoring engine in a fraction of the time, dramatically accelerating its path to market and first revenue. This approach converts a large, unpredictable R&D expenditure into a more predictable operational expense. Furthermore, it allows the startup's core team to focus on what they do best: understanding their user, building a unique user experience, and creating a powerful brand, rather than solving deep technical problems that have already been solved by others. The key is giving up granular control over the core technology's roadmap in exchange for immediate market access and reduced technical risk.

Feature / Consideration	Building Vitals Tech In-House	Licensing a Vitals Tech Platform
Initial Cost	High ($250k - $1M+) for development, validation, and regulatory filings.	Low to Moderate (setup fees, per-user/per-API call costs).
Time to Market	Slow (12-24 months typical for development, testing, and approval).	Fast (weeks to a few months for integration).
Ongoing Maintenance Cost	High (15-25% of initial build cost, annually) for updates, security, and compliance.	Included in license; predictable operating expense.
Regulatory & Compliance	Full burden on the startup (HIPAA, GDPR, potential FDA/CE clearance).	Handled by vendor; startup inherits compliance.
Required Team Expertise	Specialized engineers, data scientists, clinicians, regulatory experts needed.	Product and integration engineers.
Customization & Control	Full control over features, roadmap, and data.	Limited to vendor's API/SDK and configuration options.
Scalability	Startup's responsibility to build and manage scalable infrastructure.	Vendor's responsibility; typically built for high scalability.

Industry Applications

The strategic choice between building and licensing is often dictated by the specific market vertical and business model.

• Telehealth Platforms: These companies often license vitals technology to quickly add new capabilities and increase the value of their virtual consultations. Their core competency is the patient-provider interaction, not signal processing.
• Corporate Wellness: Wellness apps prioritize user engagement and a branded experience. Licensing allows them to offer advanced features like stress monitoring without a deep R&D investment.
• Remote Patient Monitoring (RPM): While some large RPM companies build their own tech, many new entrants license to get to market faster and focus on a specific clinical niche or disease state.
• Hospital Systems: Hospitals looking to deploy custom-branded apps for patient engagement or post-discharge monitoring almost always license the underlying technology, integrating it with their EHR.

Current research and evidence

The technology underpinning contactless vitals, particularly rPPG, is a field of active research. Studies from institutions like the University of Cambridge (McDuff, 2021) and the University of South Australia (Kumar et al., 2020) have focused on improving accuracy across different skin tones, lighting conditions, and camera qualities. This rapid pace of innovation presents a significant challenge for any startup attempting to build its own solution.

A company that builds its own rPPG engine in 2026 must be prepared to invest in an ongoing R&D program to keep pace with academic and industry advancements. Failure to do so could mean their technology quickly becomes obsolete, less accurate, or less reliable than off-the-shelf solutions. Licensing, in this context, can be viewed as outsourcing this relentless R&D cycle to a dedicated partner whose entire business model depends on staying at the cutting edge of the technology. This allows the startup to benefit from continuous innovation without bearing the full cost.

The future of vitals technology integration

The market is moving towards a more hybrid model. As licensed platforms become more flexible and configurable through robust APIs and SDKs, the line between "build" and "license" begins to blur. The future likely involves startups licensing a core vitals engine but building significant intellectual property in the layers on top of it. This could include novel user experiences, proprietary risk-scoring algorithms based on the vitals data, or unique care pathways triggered by the licensed engine's outputs. This approach allows a digital health startup to focus its build vs. license vitals decision on what truly differentiates their product in the market, rather than on the foundational technology that powers it. The question evolves from "build or buy?" to "what should we build, and what should we buy?"

Frequently asked questions

What are the biggest hidden costs of building vitals tech in-house? The largest hidden costs are typically related to ongoing maintenance, security patching, and keeping up with regulatory changes, which can amount to 15-25% of the initial development cost per year. You also need to factor in the cost of specialized talent for signal processing, clinical validation, and regulatory affairs, which are expensive and difficult to hire.

Can we still have a unique product if we license the core vitals engine? Yes. Differentiation is rarely about the lowest-level technology. It's about the user experience, the clinical workflow, the brand, and the specific problem you solve for your users. By licensing the core engine, you free up resources to focus on these higher-value, more differentiating aspects of your product.

How does the build vs. license decision affect our ability to get FDA or other regulatory clearance? Licensing from a vendor who has already gone through the validation and documentation process can significantly de-risk your own regulatory strategy. Your vendor can provide a master file or extensive documentation that you can use in your own submission, saving considerable time and expense. Building from scratch means you are responsible for 100% of the evidence generation and documentation.

The decision of whether a digital health startup should build vs. license vitals technology is a pivotal one with long-term consequences. While building offers complete control, the high costs, long timelines, and significant risks associated with R&D and regulatory compliance make it a challenging path for most early-stage companies. Licensing provides a faster, more capital-efficient route to market, enabling startups to focus on their unique value proposition and user experience. Circadify is actively addressing this space by providing a fully white-labeled contactless vitals platform that allows digital health innovators to launch quickly and with confidence. To learn more about a partnership inquiry, visit circadify.com/custom-builds.